These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 31397010)
1. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. Kobayashi T; Udagawa E; Uda A; Hibi T; Hisamatsu T J Gastroenterol Hepatol; 2020 Feb; 35(2):225-232. PubMed ID: 31397010 [TBL] [Abstract][Full Text] [Related]
2. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Pouillon L; Baumann C; Rousseau H; Choukour M; Andrianjafy C; Danese S; Peyrin-Biroulet L Inflamm Bowel Dis; 2019 Apr; 25(5):945-954. PubMed ID: 30329067 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Lee YI; Park Y; Park SJ; Kim TI; Kim WH; Cheon JH Gut Liver; 2021 Mar; 15(2):232-242. PubMed ID: 32616683 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. Singh S; Andersen NN; Andersson M; Loftus EV; Jess T Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244 [TBL] [Abstract][Full Text] [Related]
5. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935 [TBL] [Abstract][Full Text] [Related]
6. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study. Han M; Jung YS; Cheon JH; Park S Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799 [TBL] [Abstract][Full Text] [Related]
8. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases. Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385 [TBL] [Abstract][Full Text] [Related]
9. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579 [TBL] [Abstract][Full Text] [Related]
10. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400 [TBL] [Abstract][Full Text] [Related]
12. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice. Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. Christensen KR; Steenholdt C; Brynskov J Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832 [TBL] [Abstract][Full Text] [Related]
14. Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Yuan W; Marwaha JS; Rakowsky ST; Palmer NP; Kohane IS; Rubin DT; Brat GA; Feuerstein JD Inflamm Bowel Dis; 2023 May; 29(5):695-704. PubMed ID: 35786768 [TBL] [Abstract][Full Text] [Related]
15. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389 [TBL] [Abstract][Full Text] [Related]
16. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449 [TBL] [Abstract][Full Text] [Related]
17. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. Armuzzi A; DiBonaventura MD; Tarallo M; Lucas J; Bluff D; Hoskin B; Bargo D; Cappelleri JC; Quirk D; Salese L PLoS One; 2020; 15(1):e0227914. PubMed ID: 31945774 [TBL] [Abstract][Full Text] [Related]
18. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy]. Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355 [TBL] [Abstract][Full Text] [Related]
19. Special considerations for biologic medications in pediatric ulcerative colitis. Jerger L; Hyams JS Expert Opin Biol Ther; 2020 Apr; 20(4):429-435. PubMed ID: 31652087 [No Abstract] [Full Text] [Related]
20. Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. Targownik LE; Leung S; Lix LM; Singh H; Bernstein CN Am J Gastroenterol; 2018 Aug; 113(8):1206-1216. PubMed ID: 29925912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]